Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 836880

Next Previous
Drug Profile

BI 836880

Alternative Names: Anti-VEGF/Ang2 Nanobody®; BI-836880; Bi-specific Anti-VEGF/Ang2 Nanobody®; VEGF/Ang2 Nanobody ®

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ablynx
  • Developer Boehringer Ingelheim
  • Class Antineoplastics; Bispecific antibodies; Eye disorder therapies; Immunotherapies
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anal cancer; Solid tumours
  • Phase I/II Wet age-related macular degeneration
  • No development reported Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Squamous cell cancer

Most Recent Events

  • 28 May 2025 No recent reports of development identified for preclinical development in Nasopharyngeal-cancer in Germany (Intraperitoneal, Injection)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Liver-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV, Infusion)
  • 28 Mar 2025 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top